Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Since oral gabapentin is frequently used for neuropathic pain, Boardman et al 23 hypothesized that topical gabapentin could be effective in treating vulvodynia. Records were gathered of pre- and postmenopausal women diagnosed with localized or generalized vulvodynia over a 6-year period and were narrowed to those treated with topical gabapentin. Patient demographic and medical characteristics, including present and prior treatment for vulvodynia, were routinely collected. The final outcome was defined by a comparison between pretreatment and posttreatment mean pain scores based on a discrete visual analog scale of 0 to 10. The topical route also avoids the systemic complications of gabapentin such as somnolence, dizziness, and peripheral edema. This study aimed to perform a narrative synthesis of studies investigating the use of topical gabapentin in the treatment of vulvodynia. The primary outcome was a change in pain score following treatment with topical This was an 18-week, multicenter, placebo-controlled, double-blinded RCT with a two-treatment, two-period crossover design that studied the efficacy of extended release gabapentin (Gralise™) (1200–3000 mg/day) for localized provoked vulvodynia (previously known as vulvar vestibulitis). The study consisted of 8 phases:1) a 2-week screening Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change –4.77, 95% confidence RESULTS: Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change –4.77, 95% Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change -4.77, 95% confidence interval 6% Gapapentin in Lipoderm is helpful in vulodynia. Interesting how they made it up. Obstet Gynecol. 2008 Sep;112(3):579-85. Topical gabapentin in the treatment of localized and generalized vulvodynia. RESULTS: Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change -4.77, 95% confidence Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change -4.77, 95% confidence interval Vulvodynia is not a single entity. It is a heterogeneous condition characterized by multiple triggers, making it challenging to define a reference standard for its treatment. In this manuscript we selected all articles including the following key criteria: “vulvodynia”. Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. recommend topical gabapentin in the treatment of vulvodynia in the 2016 European guidelines, though it has been removed from the most recent guidelines for reasons unknown ( 28 ). Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008; 112:579-585. Andrews JC. Vulvodynia interventions- systematic review and evidence grading. Obstet Gynecol Survey. 2011:66(5):299-315. Gabapentin appears to be very effective in the treatment of generalized vulvodynia, unprovoked. It has a very low side effect profile. Certain patients may be less likely to benefit from gabapentin, including those with the comorbidity of sleep disturbance. Patients with symptoms of longer-standing Results: Between January 2001 and December 2006, 51 women with vulvodynia (19 or 37% with generalized vulvodynia, 32 or 63% with localized) were treated with 2% to 6% gabapentin. After a minimum of 8 weeks of therapy, the mean pain score among the 35 evaluable women was significantly reduced from 7.26 to 2.49 (mean change -4.77, 95% confidence pharmacological treatment such as oral gabapentin are used in the treatment of vulvodynia. Topical formulations of gabapentin have shown promise in animal models and case reports investigating its use in other pain conditions. The topical route also avoids the systemic complications of gabapentin such as somnolence, dizziness, and peripheral edema. 1,2 Patients with vulvodynia may experience vulvovestibular burning, stinging, itching, irritation, tenderness, or any combination of these.2 The 2015 consensus guidelines for vulvodynia further characterize the condition based on its location (localized or generalized), provocation (provoked or spontaneous), onset (primary vs secondary), and Vulvodynia is a poorly understood yet common and highly uncomfortable chronic condition with no satisfactory treatment. Extrapolating from the usefulness of oral gabapentin for vulvodynia, investigators conducted a retrospective case series review of 51 patients who had been treated with topical gabapentin for generalized or localized vulvodynia. The topical route also avoids the systemic complications of gabapentin such as somnolence, dizziness, and peripheral edema. This study aimed to perform a narrative synthesis of studies investigating the use of topical gabapentin in the treatment of vulvodynia. The primary outcome was a change in pain score following treatment with topical
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |